ReviewThe Lancet. Microbe2026
WHO assessment of the preclinical antifungal pipeline: evaluating innovation and preparedness in the face of emerging fungal threats.
Review in The Lancet. Microbe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Life-threatening invasive and mucosal fungal infections are a major, increasingly complex global health problem. Among all population groups, individuals who are immunocompromised face the greatest risk of contracting such infections, and the size of these global populations is growing at a swift pace. Climate change also affects the dynamics of fungal infections. Commercially available antifungal drugs often have a narrow-spectrum activity and below-optimal safety profile. Drug resistance to antifungals is also rising, and the use of fungicides in agriculture plays a role in resistance development. In this Review, we aim to provide an overview of the current preclinical research and development landscape of antifungal agents and to critically assess the extent to which current efforts address fungal priority pathogens according to the WHO priority list. We identified 22 programmes in the preclinical pipeline, including 13 for novel agents, four exploring new routes of administration, two investigating new formulations of existing antifungals, and three repurposed monoclonal antibody programmes. These preclinical programmes are at the initial stages (with nine [40·9%] of 22 programmes in the earliest preclinical stage) and insufficiently mature to enter robust clinical developmental stages, requiring comprehensive safety characterisation before advancement. Thus, there is a crucial need to develop novel antifungal agents with improved potency, broad-spectrum activity, and enhanced safety profiles and pharmacological features.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.